泌尿系统疾病中的线粒体功能障碍
该综述以PubMed为主数据库检索截至2025年8月的文献,聚焦临床或人体研究,总结线粒体功能障碍与下尿路症状(LUTS)相关疾病(如衰老、代谢综合征、糖尿病、压力性尿失禁、良性前列腺增生和膀胱过度活动症)的关联。文章指出线粒体功能障碍是LUTS相关疾病的潜在新交叉点,但需更多投入以明确机制和探索新治疗。
要点
- 线粒体功能障碍可能与多种LUTS相关疾病有关。
- 遗传性线粒体疾病患者LUTS发生率高于一般人群。
- 线粒体调节剂治疗LUTS的潜力需谨慎评估。
核心结论
- 线粒体功能障碍是LUTS相关疾病(包括衰老、代谢综合征、糖尿病、压力性尿失禁、良性前列腺增生和膀胱过度活动症)的潜在新交叉点。
- 初步研究令人鼓舞,但需更多投入以识别潜在机制和新的潜在治疗方法。
研究设计与样本
- 综述,以PubMed为主要数据库进行文献检索,纳入2025年8月前发表的研究,重点关注临床或人体研究。
- 排除线粒体功能障碍研究少于三篇的泌尿系统疾病,且泌尿系统癌症研究不在综述范围内。
主要发现
- 2011年估计近20亿人(占世界人口45.2%)经历一种或多种LUTS。
- 遗传性线粒体疾病患者LUTS发生率高于一般人群。
临床怎么用
- 线粒体调节剂正在其他疾病中进行试验,应仔细考虑其作为LUTS治疗的潜力。
局限性
- 线粒体功能障碍是泌尿疾病研究中被调查不足的领域。
- 需要更多投资来识别潜在机制和新潜在治疗方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lower urinary tract symptoms (LUTS) can result from several conditions, including but not limited to benign prostatic hyperplasia, diabetes, stress urinary incontinence, and metabolic syndrome. In 2011, it was estimated that nearly 2 billion people (45.2% of the world population) experience one or more LUTS. To date, there is no single underlying mechanism identified in lower urinary tract symptoms or the associated conditions. However, a recent body of evidence has demonstrated that mitochondrial dysfunction may contribute to conditions associated with LUTS. Furthermore, patients with inherited mitochondrial disease exhibit lower urinary tract symptoms at rates above the general population. Given that mitochondrial dysfunction is an under-investigated area of urinary disease research, this review aims to summarize the existing literature in the field. METHODS: PubMed was used as the primary database for literature search. Keywords included "lower urinary tract symptoms", "mitochondria", "urinary dysfunction"; additionally, once identified, further disease-specific searches were performed (e.g., "urinary dysfunction in type 1 diabetes"). Studies published earlier than August 2025 were included, and a specific focus was placed on clinical or human studies. Urologic conditions lacking at least three publications investigating mitochondrial dysfunction were not included; studies examining mitochondrial dysfunction in urologic cancers were also outside the scope of this review. RESULTS AND CONCLUSIONS: Mitochondrial dysfunction is a potential novel intersection of diseases associated with LUTS, including aging, metabolic syndrome, diabetes, stress urinary incontinence, benign prostatic hyperplasia, and overactive bladder. While initial studies are promising, more investment into identifying underlying mechanisms and new potential treatments is needed. Additionally, as mitochondrial modulators undergo trial as treatments in other conditions, careful consideration should be given to their potential as treatments for LUTS.
引用
- Adrian AE, Boucher NJ, McVary KT, et al. Mitochondrial dysfunction in urologic disease. Prostate Cancer Prostatic Dis. 2026. PMID: 41876711. doi:10.1038/s41391-026-01097-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。